Filing Details
- Accession Number:
- 0001169245-21-000125
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-23 18:50:15
- Reporting Period:
- 2021-11-19
- Accepted Time:
- 2021-11-23 18:50:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1169245 | Phasebio Pharmaceuticals Inc | PHAS | Pharmaceutical Preparations (2834) | 030375697 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1803271 | Glen Burkhardt | C/O Phasebio Pharmaceuticals, Inc. 1 Great Valley Parkway, Suite 30 Malvern PA 19355 | Vp, Human Resources | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-11-19 | 5,766 | $2.01 | 5,766 | No | 4 | A | Direct | |
Common Stock | Disposition | 2021-11-19 | 5,766 | $2.37 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- These shares were acquired under the PhaseBio Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.